{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:54:35Z","timestamp":1763535275623},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2334-13-583","type":"journal-article","created":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T09:01:33Z","timestamp":1386666093000},"source":"Crossref","is-referenced-by-count":18,"title":["Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey"],"prefix":"10.1186","volume":"13","author":[{"given":"Banu","family":"Sancak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Server","family":"Yagci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"G\u00fcr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"G\u00fclay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilara","family":"Ogunc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcner","family":"S\u00f6yletir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ata Nevzat","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devrim \u00d6zt\u00fcrk","family":"D\u00fcndar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe Willke","family":"Top\u00e7u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"Aksit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaye","family":"Usluer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00fcneyt","family":"\u00d6zakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halis","family":"Akalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutlu","family":"Hayran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volkan","family":"Korten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,10]]},"reference":[{"issue":"5","key":"2927_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijantimicag.2008.05.007","volume":"32","author":"DI Hsu","year":"2008","unstructured":"Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A: Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents. 2008, 32 (5): 378-385. 10.1016\/j.ijantimicag.2008.05.007.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"2927_CR2","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1128\/AAC.00113-08","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008, 52 (9): 3315-3320. 10.1128\/AAC.00113-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2927_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1128\/AAC.01316-09","volume":"54","author":"HJ Adam","year":"2010","unstructured":"Adam HJ, Louie L, Watt C, Gravel D, Bryce E, Loeb M, Matlow A, McGeer A, Mulvey MR, Simor AE, et al: Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995\u20132006. Antimicrob Agents Chemother. 2010, 54 (2): 945-949. 10.1128\/AAC.01316-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2927_CR4","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1128\/JCM.02135-08","volume":"47","author":"AC Musta","year":"2009","unstructured":"Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, Khatib R: Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol. 2009, 47 (6): 1640-1644. 10.1128\/JCM.02135-08.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"2927_CR5","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/jac\/dks131","volume":"67","author":"KH Park","year":"2012","unstructured":"Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, Park SY, Moon SM, Chong YP, Kim SH, et al: Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. J Antimicrob Chemother. 2012, 67 (8): 1843-1849. 10.1093\/jac\/dks131.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2927_CR6","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1128\/JCM.00582-08","volume":"46","author":"MJ Rybak","year":"2008","unstructured":"Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN: Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol. 2008, 46 (9): 2950-2954. 10.1128\/JCM.00582-08.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2927_CR7","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1128\/JCM.02302-10","volume":"49","author":"SJ Van Hal","year":"2011","unstructured":"Van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, Paterson DL, Gosbell IB: Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol. 2011, 49 (4): 1489-1494. 10.1128\/JCM.02302-10.","journal-title":"J Clin Microbiol"},{"key":"2927_CR8","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Eighth Edition: Approved Standard M07-A8","author":"Clinical and Laboratory Standards Institute","year":"2009","unstructured":"Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Eighth Edition: Approved Standard M07-A8. 2009, PA, USA: CLSI, Wayne"},{"issue":"10","key":"2927_CR9","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1128\/JCM.00994-06","volume":"44","author":"KC Carroll","year":"2006","unstructured":"Carroll KC, Glanz BD, Borek AP, Burger C, Bhally HS, Henciak S, Flayhart D: Evaluation of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of Enterobacteriaceae. J Clin Microbiol. 2006, 44 (10): 3506-3509. 10.1128\/JCM.00994-06.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2927_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jac\/47.4.399","volume":"47","author":"M Wootton","year":"2001","unstructured":"Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP: A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001, 47 (4): 399-403. 10.1093\/jac\/47.4.399.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2927_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1128\/JCM.01508-06","volume":"45","author":"M Wootton","year":"2007","unstructured":"Wootton M, MacGowan AP, Walsh TR, Howe RA: A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol. 2007, 45 (2): 329-332. 10.1128\/JCM.01508-06.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"2927_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1128\/JCM.05520-11","volume":"50","author":"B Edwards","year":"2012","unstructured":"Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM: Is vancomycin MIC \"creep\" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol. 2012, 50 (2): 318-325. 10.1128\/JCM.05520-11.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"2927_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-010-1140-7","volume":"30","author":"J Kehrmann","year":"2011","unstructured":"Kehrmann J, Kaase M, Szabados F, Gatermann SG, Buer J, Rath PM, Steinmann J: Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?. Eur J Clin Microbiol Infect Dis. 2011, 30 (5): 677-683. 10.1007\/s10096-010-1140-7.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"2927_CR14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/jac\/dkm258","volume":"60","author":"G Steinkraus","year":"2007","unstructured":"Steinkraus G, White R, Friedrich L: Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001\u201305. J Antimicrob Chemother. 2007, 60 (4): 788-794. 10.1093\/jac\/dkm258.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"2927_CR15","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1093\/jac\/dks324","volume":"67","author":"R Reynolds","year":"2012","unstructured":"Reynolds R, Hope R, Warner M, Macgowan AP, Livermore DM: Ellington MJ, on behalf of the BEWPoRS: Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001\u201307. J Antimicrob Chemother. 2012, 67 (12): 2912-2918. 10.1093\/jac\/dks324.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2927_CR16","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1128\/AAC.00616-09","volume":"53","author":"HS Sader","year":"2009","unstructured":"Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K: Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother. 2009, 53 (10): 4127-4132. 10.1128\/AAC.00616-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2927_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/524667","volume":"46","author":"A Soriano","year":"2008","unstructured":"Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008, 46 (2): 193-200. 10.1086\/524667.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2927_CR18","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/jac\/dkr169","volume":"66","author":"R Khatib","year":"2011","unstructured":"Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S: Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011, 66 (7): 1594-1599. 10.1093\/jac\/dkr169.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2927_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ Van Hal","year":"2012","unstructured":"Van Hal SJ, Lodise TP, Paterson DL: The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012, 54 (6): 755-771. 10.1093\/cid\/cir935.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2927_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1128\/CMR.00042-09","volume":"23","author":"BP Howden","year":"2010","unstructured":"Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML: Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010, 23 (1): 99-139. 10.1128\/CMR.00042-09.","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"2927_CR21","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1128\/AAC.00904-08","volume":"52","author":"V Prakash","year":"2008","unstructured":"Prakash V, Lewis JS, Jorgensen JH: Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother. 2008, 52 (12): 4528-10.1128\/AAC.00904-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2927_CR22","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1128\/AAC.00093-09","volume":"53","author":"HS Sader","year":"2009","unstructured":"Sader HS, Rhomberg PR, Jones RN: Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009, 53 (7): 3162-3165. 10.1128\/AAC.00093-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2927_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1128\/JCM.01128-10","volume":"49","author":"SW Satola","year":"2011","unstructured":"Satola SW, Farley MM, Anderson KF, Patel JB: Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol. 2011, 49 (1): 177-183. 10.1128\/JCM.01128-10.","journal-title":"J Clin Microbiol"},{"issue":"7","key":"2927_CR24","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1128\/JCM.39.7.2439-2444.2001","volume":"39","author":"TR Walsh","year":"2001","unstructured":"Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D: Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001, 39 (7): 2439-2444. 10.1128\/JCM.39.7.2439-2444.2001.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"2927_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/jac\/dki272","volume":"56","author":"B Sancak","year":"2005","unstructured":"Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G: Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother. 2005, 56 (3): 519-523. 10.1093\/jac\/dki272.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2927_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jmii.2012.05.004","volume":"45","author":"SY Lin","year":"2012","unstructured":"Lin SY, Chen TC, Chen FJ, Chen YH, Lin YI, Kristopher Siu L, Lu PL: Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center. J Microbiol Immunol Infect. 2012, 45 (6): 435-441. 10.1016\/j.jmii.2012.05.004.","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"2927_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1128\/AAC.01133-10","volume":"55","author":"SJ Van Hal","year":"2011","unstructured":"Van Hal SJ, Paterson DL: Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011, 55 (1): 405-410. 10.1128\/AAC.01133-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2927_CR28","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1128\/JCM.01262-06","volume":"45","author":"Y Maor","year":"2007","unstructured":"Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N: Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol. 2007, 45 (5): 1511-1514. 10.1128\/JCM.01262-06.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2927_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/jac\/dkq009","volume":"65","author":"A Kirby","year":"2010","unstructured":"Kirby A, Graham R, Williams NJ, Wootton M, Broughton CM, Alanazi M, Anson J, Neal TJ, Parry CM: Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. J Antimicrob Chemother. 2010, 65 (4): 721-724. 10.1093\/jac\/dkq009.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2927_CR30","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/jac\/dkr066","volume":"66","author":"PG Kelley","year":"2011","unstructured":"Kelley PG, Gao W, Ward PB, Howden BP: Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother. 2011, 66 (5): 1057-1060. 10.1093\/jac\/dkr066.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-13-583\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T07:43:45Z","timestamp":1548229425000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-13-583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2927"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-13-583","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2013,12]]},"article-number":"583"}}